Bristol-Myers Squibb (NYSE:BMY) Shares Acquired by Sage Capital Advisors llc

Sage Capital Advisors llc boosted its position in Bristol-Myers Squibb (NYSE:BMY) by 14.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 67,286 shares of the biopharmaceutical company’s stock after acquiring an additional 8,377 shares during the quarter. Bristol-Myers Squibb accounts for about 1.5% of Sage Capital Advisors llc’s holdings, making the stock its 22nd biggest holding. Sage Capital Advisors llc’s holdings in Bristol-Myers Squibb were worth $4,303,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. True Wealth Design LLC purchased a new stake in Bristol-Myers Squibb during the fourth quarter worth approximately $26,000. GoalVest Advisory LLC purchased a new stake in shares of Bristol-Myers Squibb during the 1st quarter worth approximately $29,000. Coppell Advisory Solutions Corp. acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at $31,000. Live Oak Investment Partners acquired a new stake in Bristol-Myers Squibb during the 4th quarter worth $33,000. Finally, First Personal Financial Services lifted its position in Bristol-Myers Squibb by 67.8% in the first quarter. First Personal Financial Services now owns 495 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 200 shares during the last quarter. Hedge funds and other institutional investors own 74.98% of the company’s stock.

Bristol-Myers Squibb Price Performance

BMY stock traded down $0.03 during trading on Tuesday, hitting $58.55. The stock had a trading volume of 1,674,885 shares, compared to its average volume of 8,960,012. The company’s 50 day moving average price is $61.62 and its two-hundred day moving average price is $65.11. Bristol-Myers Squibb has a 1-year low of $58.33 and a 1-year high of $81.43. The stock has a market cap of $122.32 billion, a price-to-earnings ratio of 15.58, a price-to-earnings-growth ratio of 1.57 and a beta of 0.42. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.28 and a current ratio of 1.39.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.75 EPS for the quarter, missing analysts’ consensus estimates of $1.99 by ($0.24). Bristol-Myers Squibb had a return on equity of 50.51% and a net margin of 17.62%. The firm had revenue of $11.23 billion for the quarter, compared to analysts’ expectations of $11.81 billion. During the same quarter last year, the firm earned $1.93 earnings per share. The business’s quarterly revenue was down 5.6% compared to the same quarter last year. On average, sell-side analysts forecast that Bristol-Myers Squibb will post 7.44 EPS for the current fiscal year.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Ann Powell sold 17,986 shares of Bristol-Myers Squibb stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of $61.25, for a total value of $1,101,642.50. Following the completion of the sale, the executive vice president now owns 27,868 shares in the company, valued at approximately $1,706,915. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, EVP Ann Powell sold 17,986 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $61.25, for a total value of $1,101,642.50. Following the sale, the executive vice president now directly owns 27,868 shares of the company’s stock, valued at $1,706,915. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Robert M. Plenge sold 732 shares of Bristol-Myers Squibb stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $61.14, for a total transaction of $44,754.48. Following the completion of the transaction, the executive vice president now owns 6,584 shares in the company, valued at approximately $402,545.76. The disclosure for this sale can be found here. Insiders own 0.08% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on BMY shares. Credit Suisse Group cut their target price on Bristol-Myers Squibb from $72.00 to $66.00 in a research report on Wednesday, July 12th. Atlantic Securities cut their target price on shares of Bristol-Myers Squibb from $90.00 to $85.00 and set an “overweight” rating on the stock in a report on Friday, July 28th. Cantor Fitzgerald reiterated an “overweight” rating and set a $75.00 price target on shares of Bristol-Myers Squibb in a research note on Friday. HSBC initiated coverage on shares of Bristol-Myers Squibb in a report on Friday, July 14th. They issued a “reduce” rating and a $56.00 target price for the company. Finally, TD Cowen dropped their price target on Bristol-Myers Squibb from $80.00 to $66.00 and set a “market perform” rating on the stock in a research report on Friday. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $70.67.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.